New Anti-TB Drug Combined with Old Might Work Against All TB

Combined PA-824–moxifloxacin–pyrazinamide showed good early bactericidal activity against drug-sensitive TB and might work against multidrug-resistant disease.

New antituberculosis (anti-TB) drugs are needed to overcome two major problems: mycobacterial resistance and interactions with antiretroviral regimens. In a recent prospective, randomized study, investigators (including one who has acted as a consultant on TB drug development) compared the 14-day early bactericidal activity (EBA) of six oral anti-TB regimens in adults with untreated, drug-susceptible, uncomplicated pulmonary TB in South Africa.

The 85 participants (mean age, 30; 6 with HIV coinfection) were hospitalized and received bedaquiline (a diarylquinoline), bedaquiline/pyrazinamide, PA-824 (a nitroimidazo-oxazine)/pyrazinamide, bedaquiline/PA-824, PA-824/moxifloxacin/pyrazinamide, or current standard therapy (isoniazid/rifampicin/pyr…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

New Anti-TB Drug Combined with Old Might Work Against All TB

Topics

Reviewing Author